Precision BioSciences to Present at Guggenheim Healthcare Talks 2021 Oncology Day

DURHAM, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. DTIL a clinical stage biotechnology company dedicated to improving life with its proprietary ARCUS^® genome editing platform, today announced it will participate in the Guggenheim Healthcare Talks 2021 Oncology Day on February 11, 2021 at 2:00 PM ET.

A live webcast of the presentation will be accessible on the Company's website, www.precisionbiosciences.com, in the Investors & Media section under Events and Presentations. An archived replay of the webcasts will be available for approximately 30 days following the presentation.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS^® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

Investor Contact:

Alex Kelly

Interim Chief Financial Officer

Alex.Kelly@precisionbiosciences.com

Media Contact:

Maurissa Messier

Senior Director, Corporate Communications

Maurissa.Messier@precisionbiosciences.com